Tradewinds Global Investors’s AbbVie ABBV Stock Holding History

Tradewinds Global Investors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,917	Closed	-$263K	–	132
2015 Q2	$263K	Buy	3,917 +15	+0.4%	+$979	0.01%	112
2015 Q1	$227K	Buy	+3,902	New	+$236K	0.01%	115

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tradewinds Global Investors's ABBV Position: Q3 2015 in Review

Tradewinds Global Investors sold out of AbbVie (ABBV) in Q3 2015, closing a stake of 3,917 shares — an estimated $263K sold.

Tradewinds Global Investors first reported a position in ABBV in Q1 2015 and held it in 2 quarters. The position peaked at $263K in Q2 2015. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

Tradewinds Global Investors reported no remaining AbbVie position as of Q3 2015 after selling out during the quarter.
Tradewinds Global Investors sold 3,917 AbbVie shares in Q3 2015, an estimated $263K.
Tradewinds Global Investors first reported a position in AbbVie in Q1 2015 and held it in 2 quarters.
Tradewinds Global Investors's AbbVie position peaked at $263K in Q2 2015.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on Tradewinds Global Investors's 13F filing for Q3 2015, filed 16 Nov 2015.